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Mouse thymocytes incubated in vitro with increasing concentrations of interleukin-1 (IL-l) in the presence of phytohemagglutinin (PHA) exhibited 
a dose-dependent increase in cell proliferation, as measured by rH]thymidine incorporation. Under these conditions, there was a parallel dose- 
dependent increase in specific PHImorphine binding, with a maximum increase of approximately 5-fold over basal levels. The binding sites differ 
from classical opioid receptors in that they are not stereo-selective. Interleukin-2 was ineffective in promoting either cell proliferation or enhanced 
opioid binding, but the effects of IL-1 could be mimicked by phorbol myristate acetate (PMA), suggesting the involvement of tyrosine phosphoryla- 
tion. These results indicate that morphine-binding sites on immune cells can be regulated by cytokine activation. 
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1. INTRODUCTION 
Increasing evidence indicates that the opioid and im- 
mune systems are closely associated. Opioid agonists 
can alter a variety of immune functions in vivo and in 
vitro [l-4], and several studies suggest that some im- 
mune cells contain opioid receptors [5,6] and/or opioid 
peptides [7,8]. However, direct demonstration of these 
receptors by in vitro binding assays has been difficult, 
and many studies suggest that these receptors are quite 
different from those mediating analgesia and other in 
vivo pharmacological effects of opioids. Indeed, one re- 
cent review concluded that no study has conclusively 
demonstrated the existence of specific opioid binding 
sites on immune cells [9]. 
Considerable evidence now indicates that opioids can 
play a major role in this activation process, including 
modulation of the release and/or activity of cytokines 
[9,1 l-161. Furthermore, some studies suggest the ex- 
istence of a direct interaction at the receptor level be- 
tween opioids and cytokines. For example, naloxone 
has been reported to antagonize the actions of IL-2 on 
human natural killer cells, while ,B-endorphin inhibited 
binding of IL-2 to phytohemagglutinin (PHA)- 
stimulated lymphocytes [ 171. Another group observed 
that IL-l inhibited binding of several opioids to brain 
membranes [ 181. Conversely, Wiedermann [ 191 found 
that IL-I enhanced opioid peptide binding to frozen 
brain tissue. 
One factor that could be of importance in determin- 
ing the presence of detectable opioid receptors on im- 
mune cells is the cell’s state of activation. Many types of 
immune cells are activated by cytokines, growth factors 
that bind to specific receptors on the cell surface and in- 
itiate a cascade of metabolic events culminating in cell 
proliferation. This activation frequently includes secre- 
tion of additional cytokines and expression of their ap- 
propriate receptors. For example, activation of T-cells 
by interleukin-1 (IL-l) results in secretion of 
interleukin-2 (IL-2) as well as expression of IL-2 recep- 
tors [lo]. The action of IL-2 on these cells results in fur- 
ther proliferative events. 
Given this close relationship between opioids and 
cytokines at the level of both binding and function, it is 
plausible to suggest that opioid receptors, like those for 
cytokines, may be regulated on the immune cell by the 
cell’s state of activation. Since we recently observed 
that morphine could specifically inhibit IL-l-induced 
proliferation of thymocytes (manuscript in prepara- 
tion), it was of interest to determine whether this pro- 
liferation, in turn, altered binding of [3H]morphine to 
the thymocytes. Here we report that IL-1 activation of 
thymocytes results in a dramatic increase in specific bin- 
ding of [3H]morphine. This effect appears to depend on 
the induction of proliferation in intact cells, and not 
simply the presence of IL-l or binding to its receptor. 
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2. I, ikfaterials 
Morphine sulfate was purchased from Malinkrodt (St. Louis, MO), 
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and [‘HImorphine from Neb\ England Nuclear (Boston, XIA). PHA 
and phorbol mlristate acetate (P\lA) WI-~ obtained from Sigma 
Chemical Corp. (Sr. Louis, &IO). Recombinant mouse IL.-l and IL-2 
were purchaxd from Upstate Biotechnology, Inc. (Lake Placid, K\r ) 
and <ienzyme (Boston, MA). respectively. 
2.2. Animul5 
Harlan ICR mice Mere used in all studies. 
Thymus was removed aseptically from the animal and passed 
through a nylon mesh to dissociate the cells. The cells \%ere counted 
using the trypan blue dye exclusion method, then plated at a density 
of IO” cellr per well in a 96.well plate. Thymocyte proliferation ~a\ 
determined by stimulating the cell\ with PHA (2 mg, ml) in the 
prewnce of varying concentrations of IL.-l. .4fter 48 h, the cells were 
pulsed for 24 h with 1 /Ci of [‘Hlthymidine, then harvested, washed 
and auayed for radioactivity. 
Thymocytec were cultured tor 72 h in the prewnce of different 
mitogens, a\ detailed in section 3. The cells \cerc then harvested b> 
centrifugation at 1000~~ for 5 min and used immediately or frozen 
quickl~ In liquid nitrogen and stored at ~ 70°C. The fro/en cells were 
thawed slowly at 37”C, homogenized vxrral time5 in a Dounce 
homogenizer. and centrifuged again at 1000 !-pm for 5 min. The 
supernatant \\a\ removed and centrifuged at 1OOOOxg for 15 min. 
The pellets were resuspended in 0.32 .1l sucrose and frozen at 70°C 
until used. 
Thymocyte membranes (250 mg protein) were incubated in 2.5 m&I 
HEPES, pH 7.4 with [‘HImorphine (5 nM) in the presence or absence 
of unlabelled morphine (IOrM). The mixture wai incubated by gentle 
shaking for I h at 07C; preliminary experiment< indicated that ma\- 
imal binding occurred in this time period. The reaction was tel.- 
minatcd by filtering the cell membrane5 on K’hatman GF-B glass fiber 
filters. The filter, were then washed with 3 x 5 ml of 25 m&l HEPES, 
pH 7.4. Radioactivity of the filter\ was determined after the filtcrr 
v,ere allowed to stand in 9 ml of Gntillation cocktail (Scinti\erw) 
overnight. Specific opioid bindlng war defined a) the difference in the 
average radioactivit! bound to set\ of replicate wmple, in the 
presence and absence of unlabelled ligand. 
3. RESULTS AND DISCUSSION 
In the presence of PHA, a T-cell mitogen, and in- 
creasing concentrations of IL-l, thymocytes undergo a 
dose-dependent increase in cell number, as determined 
by incorporation of [jH]thymidine (Fig. 1A). As shown 
in Fig. lB, there was a roughly parallel increase in 
[‘HImorphine binding (per mg of thymocyte mem- 
branes), with an IL-l concentration of 1 ng/ml induc- 
ing an approximately 5-fold increase in binding. The 
[‘HImorphine binding sites present on the activated 
cells were of relatively low affinity (Kd=50 nM), and 
showed little stereo-selectivity (Fig. 2). 
In light of the reported direct interactions between 
IL-1 and opioids at the receptor level [17-191, it was im- 
portant to determine whether the enhancement of 
opioid binding by IL-l required cell proliferation, or 
could be accounted for simply by the physical interac- 
tion of IL-l with opioid receptors. When membranes 
isolated from unactivated thymocytes were pre- 
incubated for 30 min at 37°C in the presence of IL-I 
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l,is. 1. Dose-dependent stimulation ot proliferation and [‘HImor- 
phine binding in thymoclte5 by II -I. Th!mocyto \\ere cultured tiith 
PHA (2 /rg/ml) in the prewnce of incrca\lng concentratton of IL -I. 
a\ indicated. (.4) IL-I stimulation of prolifel-ation. .4fter 48 h of 
culture with PH.4 and IL-I. the cell\ were pulsed for 24 h with 1 ILrCi 
of [‘Hlthymidine. Cells \%ere then harvested. uashed, and assayed for 
radioactivity. (B) II -I stimulation of specific [‘HImorphine binding. 
After 72 h of culture \\ith PH4 and IL-I, cell\ \\eI-e harvested, men,- 
brane$ prepared. and as\aqed for [‘Hjmorphine binding. Values 
\ho\vn are means of 2 e\pcrlment\, M ith ranges indicated by the ver- 
tical bar\. 
concentrations as high as 10 ng/ml, there was no in- 
crease of [‘HImorphine binding as subsequently 
assayed (data not shown). Furthermore, as shown in 
Fig. 3B, IL-1 in the absence of PHA was able to in- 
crease [‘HImorphine binding, but only to about half the 
extent mediated by the same concentration of IL-l in 
the presence of PHA; again, the increase of opioid bin- 
ding paralleled the increase in [‘Hlthymidine incorpora- 
tion (Fig. 3A). The cytokine IL-2 given alone \vas vir- 
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Fig. 2. Effect of (~) and (+)-morphine binding to activated 
thymocytes. The experiment was carried out as in the legend to 
Fig. lA, except that [‘Hlmorhine binding was determined in the 
presence of various concentrations of (-) and (+)-morphine (unfill- 
ed and filled circles, respectively). Values are mean? of tl-iplicate 
determinations in a single, reprewntati\e experiment. 
I” w I 
tually without effect on both cell proliferation and 
opioid binding (Fig. 3A,B). 
PHA alone, at sufficiently high concentration, was 
able to induce the full increase in proliferation and bin- 
ding (Fig. 3). This is consistent with the fact that this 
mitogen stimulates secretion of endogenous IL-l. 
Treatment of the cells with PMA also induced the full 
effect on both proliferation and t3H]morphine binding 
(Fig. 3). This phorbol ester activates protein kinase C, 
a key event in cell proliferation, suggesting that IL-1 
enhancement of opioid binding may also be mediated 
through this second messenger. However, we cannot 
rule out the possibility that PMA has a direct effect on 
opioid binding, mediated through phosphorylation and 
activation of opioid receptors, rather than an indirect 
effect mediated through phosphorylation of the same 
set of proteins activated by IL-l. 
We used [jH]morphine as ligand in these studies 
because of our previous observation that morphine in- 
hibits thymocyte proliferation (manuscript in prepara- 
tion), and because morphine is one of the most com- 
monly used opioids clinically, where its effects on the 
immune system are particularly important. It remains 
to be determined whether binding of other opioid 
alkaloids, as well as opioid peptides, is similarly af- 
fected by thymocyte proliferation. However, the very 
low degree of stereo-selectivity of these binding sites in- 
dicates they are quite distinct from opioid receptors in 
the mammalian brain; in this respect, they are like other 
opioid binding sites detected on immune cells [9]. 
The physiological function, if any, of these morphine 
binding sites also remains to be elucidated, but one 
possibility is that they regulate the proliferative 
CcNlFxx PHA PMA PHA+IL-1 
Fig. 3. Effect of various stimulating agents on T-cell proliferation. 
Thymocptes were cultured for proliferation experiments as given in 
the legend to Fig. IA (panel A) or for specific [‘HImorphine binding 
as given in the legend to Fig. 1B (panel B). Concentrations of 
stimulating agents used: PHA (2Opg/ml); IL-1 (1 ng/ml); IL-2 (50000 
U/ml); PMA (IO~~M); PHA (2;Lg/ml)+ IL-I (1 n&/ml). Values rhown 
are means of triplicate determinations, \\ith standard deviations 
shobcn as vertical bars. 
response. While both enhancement and inhibition of 
immune cell proliferation have been reported by 
various investigators [9], we have found that morphine 
inhibits IL-l-induced proliferation of T-cells in this 
system, in a dose-dependent manner (manuscript in 
preparation). If this action is mediated by the same 
binding sites identified in this study, the latter could act 
as part of a negative feedback process, by which opioids 
limit proliferation of the cells. This could act as a 
counterbalance to the positive feedback system pro- 
vided by up-regulation of IL-2 receptors, activation of 
which increases cell proliferation. 
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